Engineering tumor hypersusceptibility to checkpoint immunotherapy | ||
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur | |
| dc.conicet.organizacion | Collegium Basilea. Institute for Advanced Study | |
| dc.contributor.author | Fernandez, Ariel | |
| dc.date.issued | 2017-09-04 | |
| dc.description.abstract | The immune checkpoint blockerpembrolizumab(Keytruda)hasproven successful in treating solidtumors harboring a DNA mismatchrepair (MMR) deficiency. We showthat it is possible to generate adrug-promoted phenotype mim-icking the MMR deficiency in solidtumors, and thereby to engineer ageneric hypersusceptibility to Key-truda through drug-induced meta-bolic stress on DNA synthesis. Thepotential of such drug–Keytrudacombinations as universal treat-ments for solid tumors deserves clinical evaluation. | es |
| dc.description.fil | Fil: Fernandez, Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur; Argentina. Collegium Basilea. Institute for Advanced Study; Suiza | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Fernandez, Ariel; Engineering tumor hypersusceptibility to checkpoint immunotherapy; Cell Press; Trends in Cancer; 3; 10; 4-9-2017; 675-677 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 2405-8033 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/85814 | |
| dc.journal.ciudad | Missouri | es |
| dc.journal.number | 10 | es |
| dc.journal.pagination | 675-677 | es |
| dc.journal.pais | Estados Unidos | es |
| dc.journal.title | Trends in Cancer | es |
| dc.journal.volume | 3 | es |
| dc.language.iso | eng | es |
| dc.publisher | Cell Press | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://www.cell.com/trends/cancer/fulltext/S2405-8033(17)30159-0 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.trecan.2017.08.002 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | CHECKPOINT BLOCKADE | es |
| dc.subject | DNA MISMATCH REPAIR | es |
| dc.subject | EPIGENETIC CANCER THERAPY | es |
| dc.subject | IMMUNOTHERAPY | es |
| dc.subject | PHOSPHOINOSITIDE 3-KINASE | es |
| dc.subject | SOLID TUMOR | es |
| dc.subject.classification | Biotecnología relacionada con la Salud | es |
| dc.subject.classification | Biotecnología de la Salud | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Engineering tumor hypersusceptibility to checkpoint immunotherapy | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.fbd99493-ae56-4f94-81bb-51c0391ff563_A.pdf
- Tamaño:
- 509.01 KB
- Formato:
- Adobe Portable Document Format